Retrospective multicenter study finds comparable chemotherapy response across HER2-low and HER2-null triple-negative breast cancer, suggesting distinct biological proliferation profiles.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Iwai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: